Literature DB >> 6508990

Alpha 1-acid glycoprotein concentrations and propranolol binding in elderly patients with acute illness.

J W Paxton, R H Briant.   

Abstract

Alpha 1-acid glycoprotein (AAG) concentrations and propranolol binding were investigated in the serum of elderly hospitalized patients with acute illness, and healthy elderly and young subjects. Significantly greater AAG concentrations and reduced unbound propranolol fraction were observed in the elderly with acute disease compared to the elderly controls. The greatest changes (up to five-fold) occurred with cancer, with lesser changes associated with myocardial infarction and ischaemic heart disease, acute infection, heart failure, chronic obstructive respiratory disease, and cerebrovascular accident. Various miscellaneous conditions were also associated with high AAG concentrations and enhanced propranolol binding. The healthy elderly had higher AAG concentrations and lower unbound propranolol fractions than the healthy young group. Overall there was a highly significant correlation between the propranolol binding ratio (bound/free) and the serum AAG concentration. These results suggest that the elderly population may be particularly susceptible to changes in AAG concentrations, and that during acute illness interpretation of serum concentrations of drugs which bind mainly to AAG, may require knowledge of their free fractions.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6508990      PMCID: PMC1463558          DOI: 10.1111/j.1365-2125.1984.tb02548.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  Plasma binding and the affinity of propranolol for a beta receptor in man.

Authors:  D G McDevitt; M Frisk-Holmberg; J W Hollifield; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1976-08       Impact factor: 6.875

2.  Role of concentration-dependent plasma protein binding in disopyramide disposition.

Authors:  P J Meffin; E W Robert; R A Winkle; S Harapat; F A Peters; D C Harrison
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

3.  Pharmacokinetic and clinical implications of quinidine protein binding.

Authors:  E Woo; D J Greenblatt
Journal:  J Pharm Sci       Date:  1979-04       Impact factor: 3.534

4.  Serum concentrations of free diphenylhydantoin and their relationship to clinical intoxication.

Authors:  H E Booker; B Darcey
Journal:  Epilepsia       Date:  1973-06       Impact factor: 5.864

Review 5.  Alpha 1 -acid glycoprotein and binding of basic drugs.

Authors:  J W Paxton
Journal:  Methods Find Exp Clin Pharmacol       Date:  1983-11

6.  Protein binding of several drugs in serum and plasma of healthy subjects.

Authors:  U W Wiegand; K L Hintze; J T Slattery; G Levy
Journal:  Clin Pharmacol Ther       Date:  1980-03       Impact factor: 6.875

7.  Increased plasma propranolol binding in myocardial infarction.

Authors:  P A Routledge; W W Stargel; G S Wagner; D G Shand
Journal:  Br J Clin Pharmacol       Date:  1980-04       Impact factor: 4.335

8.  Plasma protein binding of basic drugs. I. Selective displacement from alpha 1-acid glycoprotein by tris(2-butoxyethyl) phosphate.

Authors:  O Borgå; K M Piafsky; O G Nilsen
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

9.  Age and sex related levels of albumin, ceruloplasmin, alpha 1 antitrypsin, alpha 1 acid glycoprotein, and transferrin.

Authors:  C W Denko; P Gabriel
Journal:  Ann Clin Lab Sci       Date:  1981 Jan-Feb       Impact factor: 1.256

10.  Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein.

Authors:  K M Piafsky; O Borgá; I Odar-Cederlöf; C Johansson; F Sjöqvist
Journal:  N Engl J Med       Date:  1978-12-28       Impact factor: 91.245

View more
  12 in total

1.  Repository Describing an Aging Population to Inform Physiologically Based Pharmacokinetic Models Considering Anatomical, Physiological, and Biological Age-Dependent Changes.

Authors:  Felix Stader; Marco Siccardi; Manuel Battegay; Hannah Kinvig; Melissa A Penny; Catia Marzolini
Journal:  Clin Pharmacokinet       Date:  2019-04       Impact factor: 6.447

2.  Stereoselective binding of propranolol in the elderly.

Authors:  P Colangelo; M Chandler; R Blouin; P McNamara
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

Review 3.  Plasma protein binding of drugs in the elderly.

Authors:  S M Wallace; R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  1987-01       Impact factor: 6.447

4.  Pharmacokinetics of acridine-4-carboxamide in the rat, with extrapolation to humans.

Authors:  J W Paxton; D Young; I G Robertson
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 5.  The effect of respiratory disorders on clinical pharmacokinetic variables.

Authors:  A M Taburet; C Tollier; C Richard
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

6.  Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir.

Authors:  Dean Hickman; Sudthida Vasavanonda; George Nequist; Lynn Colletti; Warren M Kati; Richard Bertz; Ann Hsu; Dale J Kempf
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

Review 7.  Diltiazem. A review of its pharmacology and therapeutic use in older patients.

Authors:  A Markham; R N Brogden
Journal:  Drugs Aging       Date:  1993 Jul-Aug       Impact factor: 3.923

Review 8.  Clinical pharmacokinetic considerations in the elderly. An update.

Authors:  S Dawling; P Crome
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

9.  Protein binding and disposition of lignocaine in the elderly.

Authors:  B Cusack; K O'Malley; J Lavan; J Noel; J G Kelly
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 10.  Pharmacokinetics in the elderly.

Authors:  M Mayersohn
Journal:  Environ Health Perspect       Date:  1994-12       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.